fbpx Skip to main content

Member's Profile

Cleave Therapeutics

135 Main St Ste 1145
San Francisco,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2015
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Cleave Therapeutics
Biotech Company
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. The privately held company, based in San Francisco, is advancing CB-5339, its second-generation, small molecule VCP/p97 inhibitor, to clinical studies in acute myeloid leukemia (AML), while the National Cancer Institute (NCI) will sponsor and evaluate CB-5339 in clinical studies of patients with solid tumors.
Related News
No related news posted by this Member